Scribe Therapeutics Inc. (SCTX) Stock Forecast
SCTX analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 4 analysts
- Price target
- $57.00 average of analyst targets
- Upside to target
- +183.9% from the latest close
- Next earnings
- December 2, 2026 EPS estimate $-0.42
- 52-week range
- $15.00 – $37.25
SCTX analyst ratings
4 analystsNumber of analysts at each rating.
SCTX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
SCTX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.03 | −$1.46 | −$0.75 | — | — | 3 |
| Current fiscal year (2026) | −$5.59 | −$6.63 | −$4.55 | — | — | 2 |
| Next fiscal year (2027) | −$3.62 | −$4.47 | −$3.11 | −$5.59 | +35.3% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
SCTX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $3.7M | $0 | $11.0M | — | 5 |
| Current fiscal year (2026) | $11.6M | $4.0M | $26.1M | — | 5 |
| Next fiscal year (2027) | $6.7M | $0 | $10.9M | −41.8% | 5 |
SCTX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
SCTX revenue: reported and forecast
SCTX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.00 | $0.00 | $0.00 | −$1.05 | −$1.03 | — | 0 up · 0 down |
| Current fiscal year (2026) | $0.00 | $0.00 | $0.00 | −$5.92 | −$5.59 | — | 0 up · 0 down |
| Next fiscal year (2027) | $0.00 | $0.00 | $0.00 | −$3.45 | −$3.62 | — | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
SCTX earnings surprises
Reported EPS vs the consensus estimate for the last 1 quarters; SCTX beat in 1 of 1.
What analysts expect from SCTX
4 analysts cover Scribe Therapeutics; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $57.00, 183.9% above the latest close of $20.08. Analysts expect earnings of −$5.59 per share for 2026. For 2027 the average estimate is −$3.62 per share on revenue of $6.7 million. Scribe Therapeutics beat the EPS estimate in 1 of the last 1 quarters.
Related: SCTX income statement, SCTX key metrics, SCTX chart. See the SCTX stock overview for the latest quote and news.
SCTX forecast FAQ
What is Scribe Therapeutics's price target?
The average analyst price target for Scribe Therapeutics is $57.00, 183.9% above the latest close of $20.08.
Is Scribe Therapeutics a buy, hold or sell?
Of 4 analysts covering Scribe Therapeutics, 4 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Scribe Therapeutics's EPS forecast?
Analysts forecast −$5.59 per share for 2026 (range −$6.63 to −$4.55); for 2027 the estimate is −$3.62.
What is Scribe Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $11.6 million; for 2027 it is $6.7 million.
When does Scribe Therapeutics report earnings?
Scribe Therapeutics is expected to report results for the quarter ending September 30, 2026 on December 2, 2026; the EPS estimate is $-0.42.
Does Scribe Therapeutics usually beat earnings estimates?
Scribe Therapeutics reported EPS at or above the analyst estimate in 1 of the last 1 quarters.